Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Short-term Investments: 2010-2025

Historic Short-term Investments for Iovance Biotherapeutics (IOVA) over the last 6 years, with Sep 2025 value amounting to $142.7 million.

  • Iovance Biotherapeutics' Short-term Investments was N/A to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.7 million, marking a year-over-year change of. This contributed to the annual value of $208.1 million for FY2024, which is 26.13% up from last year.
  • Iovance Biotherapeutics' Short-term Investments amounted to $142.7 million in Q3 2025, which was down 15.42% from $168.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Short-term Investments high stood at $222.0 million for Q1 2024, and its period low was $20.9 million during Q2 2023.
  • Moreover, its 3-year median value for Short-term Investments was $165.0 million (2023), whereas its average is $143.5 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first skyrocketed by 168.10% in 2024, then fell by 15.30% in 2025.
  • Iovance Biotherapeutics' Short-term Investments (Quarterly) stood at $165.0 million in 2023, then grew by 26.13% to $208.1 million in 2024, then declined by 15.30% to $142.7 million in 2025.
  • Its Short-term Investments stands at $142.7 million for Q3 2025, versus $168.7 million for Q2 2025 and $188.0 million for Q1 2025.